Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | HTR3A | P46098 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12728739 | 0.93 | KCNH2 (0.51) | KCNH2HTR3AHRH3SIGMAR1MAPK13 | |
| SCHEMBL2576067 | 0.84 | ACHE (0.43) | KCNH2HTR3AACHEHRH3SIGMAR1 | |
| SCHEMBL14134817 | 0.80 | ALDH1A1 (0.42) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL12651105 | 0.76 | COMT (0.51) | MAPK13MAPK12MAPK11MAPK14MEN1 | |
| SCHEMBL12650889 | 0.76 | PTGS2 (0.39) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL12728406 | 0.76 | CSNK1D (0.42) | KCNH2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL7780005 | 0.76 | PTGS2 (0.67) | — | |
| SCHEMBL2581775 | 0.76 | HRH1 (0.44) | KCNH2HTR3ADRD2DRD3HRH3 | |
| SCHEMBL2580788 | 0.75 | LTA4H (0.43) | KCNH2HRH3MEN1HTTKMT2A | |
| SCHEMBL12728412 | 0.75 | BRAF (0.38) | MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919507-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2011-04-05 | — | — | US | disclosed |
| US-7741329-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2010-06-22 | — | — | US | disclosed |
| US-20090093478-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.I.C. | 2009-04-09 | — | — | US | disclosed |
| US-20090029986-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. | 2009-01-29 | — | — | US | disclosed |
| US-20090012073-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. | 2009-01-08 | — | — | US | disclosed |
| US-7432270-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012073-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | KCNH2 1182/4885HTR3A 55/4885ACHE 121/4885 |
| US-20090093478-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | KCNH2 1182/4885HTR3A 55/4885ACHE 121/4885 |
| US-20090029986-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | KCNH2 1182/4885HTR3A 55/4885ACHE 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.